(Q33809743)

29 July 2017

1 reference

title

Clinical experience with soluble TNF p75 receptor in rheumatoid arthritis (English)

1 reference

29 July 2017

0 references

1 reference

Franklin CM

1

1 reference

29 July 2017

1 December 1999

1 reference

Seminars in Arthritis and Rheumatism

29 July 2017

1 reference

29 July 2017

29

1 reference

29 July 2017

3

1 reference

29 July 2017

172-181

1 reference

Survival, prognosis, and causes of death in rheumatoid arthritis

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980028-6

7 January 2021

The mortality of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980028-6

7 January 2021

Cytokine expression in chronic inflammatory disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980028-6

7 January 2021

Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980028-6

7 January 2021

Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980028-6

7 January 2021

Pig interleukin 1. Purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980028-6

7 January 2021

Antagonism of the IL-6 cytokine subfamily--a potential strategy for more effective therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980028-6

7 January 2021

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980028-6

7 January 2021

Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980028-6

7 January 2021

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980028-6

7 January 2021

Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980028-6

7 January 2021

Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980028-6

7 January 2021

Interleukin-1 receptor antagonist: role in biology

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980028-6

7 January 2021

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980028-6

7 January 2021

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980028-6

7 January 2021

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980028-6

7 January 2021

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980028-6

7 January 2021

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980028-6

7 January 2021

Methotrexate in rheumatoid arthritis. An update

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980028-6

7 January 2021

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980028-6

7 January 2021

Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980028-6

7 January 2021

The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980028-6

7 January 2021

Early, aggressive therapy for rheumatoid arthritis: concerns, descriptions, and estimate of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980028-6

7 January 2021

10.1016/S0049-0172(99)80028-6

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10622681